Press

Aion Therapeutic Announces Proposed Non-Brokered Private Placement Offering of Units

Jul 5 • 1 min read

Aion Therapeutic Inc. (CSE: AION) is pleased to announce that it plans to undertake a non-brokered private placement of up to 50,000,000 units (“Units”) to raise gross proceeds of up to $500,000.00 (the “Unit Offering”). The Units will be offered at a price of $0.01, with each Unit consisting of one common share (“Share”) and one half of one common…

Small Pharma Announces Management Team Change

Jul 5 • 3 min read

Small Pharma Inc. (TSXV: DMT / OTCQB: DMTTF), a biotechnology company focused on short-acting psychedelic-assisted therapies for mental health conditions, today announces that Mr. Peter Rands, co-founder, Chief Innovation & Intellectual Property Officer and former Chief Executive Officer of the Company, has left his positions as an executive officer and director of the Company and…

Small Pharma Announces SPL028 R&D Strategy Update

Jul 5 • 4 min read

Small Pharma Inc. (TSXV: DMT / OTCQB: DMTTF), a biotechnology company focused on short-duration psychedelic-assisted therapies for mental health conditions, is pleased to announce a research and development (R&D) strategy update, aimed at expediting its clinical program of SPL028, the Company’s novel deuterated N, N-dimethyltryptamine (“DMT”) compound with multi-layered intellectual property (“IP”) protection. SPL028 is…

Wesana Health Announces Closing of Previously Announced SANA-013 Asset Sale

Jul 5 • 3 min read

Wesana Health Holdings Inc. (CSE:WESA / OTCQB:WSNAF), today announced the successful closing of the sale by Wesana Health Inc. (“WHI”), a subsidiary of the Company, of WHI’s right and interest in the SANA-013 intellectual property and development related assets pursuant to the terms of the asset purchase agreement with Lucy Scientific Discovery Inc. (NASDAQ:LSDI) (“Lucy”)…

FSD Pharma Inc. Announces Results of Annual General and Special Meeting of Shareholders

Jul 3 • 4 min read

FSD Pharma Inc. (NASDAQ: HUGE / CSE: HUGE / FRA: 0K9A), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative, inflammatory and metabolic disorders, announced today the results of its annual general and special meeting of shareholders (“ AGSM ”), held online and in virtual-only format…

Pages: 123456789101112131415161718192021222324252627282930313233343536373839404142434445464748495051525354555657585960616263646566676869707172737475767778798081828384858687888990919293949596979899100101102103104105106107108109110111112113114115116117118119120121122123124125126127128129130131132133134135136137138139140141142143144145146147148149150151152153154155156157158159160161162163164165166167168169170171172173174175176177178179180181182183184185186187188189190191192193194195196197198199200201202203204205206207208209210211212213214215216217218219220221222223224225226227228229230231232233234235236237238239240241242243244245246247248249250251252253254255256257258259260261262263264265266267268269270271272273274275276277278279280281282283284285286287288289290291292293294295296297298299300301302303304305306307308309310311312313314315316317318319320321322323324325326327328329330331332333334335336337338339340341342343344345346347348349350351352353354355356357358359360361362363364365366367368369370371372373374375376377378379380381382383384385386387388389390391392393394395396397398399400401402403404405406407408409410411412413414415416417418419420421422423424425426427428429430431432433434435436437438439440441